Shilpa Medicare trades jubilantly as its arm gets marketing authorization permission for Adalimumab injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Shilpa Medicare is currently trading at Rs.270.45, up by 24.30 points or 9.87% from its previous closing of Rs. 246.15 on the BSE.
The scrip opened at Rs. 253.00 and has touched a high and low of Rs. 274.50 and Rs. 253.00 respectively. So far 538610 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 438.00 on 20-Jul-2022 and a 52 week low of Rs. 222.40 on 28-Mar-2023.
Last one week high and low of the scrip stood at Rs. 275.70 and Rs. 245.00 respectively. The current market cap of the company is Rs. 2256.85 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 14.28% and 35.71% respectively.
Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals (SBPL) has received the marketing authorization permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of adalimumab higher concentration formulation (100mg/mL) in India. This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
